Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses

Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses

For cancer vaccines, the selection of optimal tumor-associated antigens (TAAs) that can maximize the immunogenicity of the vaccine without causing unwanted adverse effects is challenging. In this study, we developed two engineered Human epidermal growth factor receptor 2 (HER2) antigens, K965 and K1...

Full description

Bibliographic Details
Main Authors: Insu Jeon, Jeong-Mi Lee, Kwang-Soo Shin, Taeseung Kang, Myung Hwan Park, Hyungseok Seo, Boyeong Song, Choong-Hyun Koh, Jeongwon Choi, Young Kee Shin, Byung-Seok Kim, Chang-Yuil Kang
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Vaccines
Subjects:
HER2
p95HER2
cancer vaccine
Online Access:https://www.mdpi.com/2076-393X/8/3/403

Internet

https://www.mdpi.com/2076-393X/8/3/403

Similar Items